LUN.CO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jan 1970 @ 01:00):

Stats
Dagens volum	346 952
Gjennomsnittsvolum	371 694
Markedsverdi	0.00
Last Dividend	DKK0 ( N/A )
Next Dividend	DKK0 ( N/A )
P/E	31.01
ATR14	DKK0 (0.00%)

H. Lundbeck A/S Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

H. Lundbeck A/S Økonomi

Annual	2021
Omsetning:	DKK16.30B
Bruttogevinst:	DKK12.65B (77.62 %)
EPS:	DKK6.63

FY	2021
Omsetning:	DKK16.30B
Bruttogevinst:	DKK12.65B (77.62 %)
EPS:	DKK6.63

FY	2020
Omsetning:	DKK17.67B
Bruttogevinst:	DKK13.50B (76.42 %)
EPS:	DKK7.95

FY	2019
Omsetning:	DKK17.36B
Bruttogevinst:	DKK13.97B (80.50 %)
EPS:	DKK13.42

Financial Reports:

No articles found.

H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.